KAT5 and breast carcinoma: Recently a high-throughput screening has led to the identification of TH1834 as Tip60-selective inhibitor by using computational tools to design drugs based on the binding pocket of Tip60 TH1834 inhibits Tip60 in vitro and can sensitize breast cancer cells to ionizing radiation [161].